drugset / Trial / NCT04636567

Open-label Study to Evaluate Nerindocianine as a Surgical Aid in Ureter Delineation During Minimally Invasive Surgery

NCT04636567 ↗

Phase 2 Withdrawn Li-Cor, Inc.
NaSingle-groupOpen-labelDiagnostic

Summary

Phase 2, multicenter, efficacy and safety study evaluating the use of nerindocianine for the delineation of abdominopelvic ureter anatomy via near infrared fluorescence imaging during minimally invasive lower abdominal surgery (e.g. gynecological, lower gastrointestinal, or other lower abdominal surgery).

Timeline

Start
2021-03
Primary completion
2021-07
Completion
2021-12

Outcome

Outcome not reported

Stopped (Business): “Clinical program has been suspended for business reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerindocianine Diagnostic / imaging agent 0.055 mg/kg Intravenous